5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1 H)-one and processes for their preparation

Information

  • Patent Grant
  • 9850215
  • Patent Number
    9,850,215
  • Date Filed
    Friday, June 3, 2016
    8 years ago
  • Date Issued
    Tuesday, December 26, 2017
    6 years ago
Abstract
Provided herein are 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one and processes for their preparation which may include the use of an alkali carbonate and an alkylating agent
Description
FIELD

Provided herein are 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one and processes for their preparation.


BACKGROUND AND SUMMARY

U.S. patent application Ser. No. 13/090,616, U.S. Pub. No. 2011/0263627, describes inter alia certain N3-substituted-N1-sulfonyl-5-fluoropyrimidinone compounds and their use as fungicides. The disclosure of the application is expressly incorporated by reference herein. This patent application describes various routes to generate N3-substituted-N1-sulfonyl-5-fluoropyrimidinone compounds. It may be advantageous to provide more direct and efficient methods for the preparation, isolation, and purification of N3-substituted-N1-sulfonyl-5-fluoropyrimidinone fungicides and related compounds, e.g., by the use of reagents and/or chemical intermediates and isolation and purification techniques which provide improved time and cost efficiency.


Provided herein are 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one and processes for their preparation. In one embodiment, provided herein is a process for the preparation of compounds of Formula III:




embedded image



wherein R1 is selected from:




embedded image



and R2 is selected from:




embedded image



which comprises contacting compounds of Formula II (shown below) with a base, such as an alkali carbonate, e.g., sodium-, potassium-, cesium-, and lithium carbonate (Na2CO3, K2CO3, Cs2CO3, and Li2CO3, respectively) or an alkali alkoxide, for example, potassium tert-butoxide (KOtBu) and an alkylating agent, such as an alkyl halide of Formula R2—X, wherein R2 is as previously defined and X is a halogen, e.g., iodine, bromine, and chlorine, in a polar solvent, such as N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide (DMA), N-methylpyrrolidone (NMP), acetonitrile (CH3CN), and the like, at concentrations from about 0.1 molar (M) to about 3 M. In some embodiments, a molar ratio of compounds of Formula II to the base is from about 3:1 to about 1:1 and a molar ratio of compounds of Formula II to alkylating agent is from about 1:1 to about 3:1. In other embodiments, molar ratios of compounds of Formula II to the base and compounds of Formula II to the alkylating agent of about 2:1 and 1:3, respectively, are used. In some embodiments, the reactions are conducted at temperatures between −78° C. and 90° C., and in other embodiments, the reactions are conducted between 22° C. and 60° C.




embedded image


It will be understood by those skilled in the an that manipulation of the reaction parameters described above may result in the formation of product mixtures comprised of compounds of Formulas II, III, and IV, as shown in Scheme 1, wherein the ratios of compounds of Formulas II, III, and IV formed is from about 0:2:1 to about 1:2:0. In some embodiments, compositions comprising mixtures of compounds of Formulas II and III are preferred, as isolation and purification can be achieved through precipitation and recrystallization, and the intermediate compounds of Formula II can be recovered and recycled. In contrast, compositions comprising mixtures of compounds of Formulas III and IV require chromatographic separation to give III along with the undesired dialkylated by-product of Formula IV.




embedded image


In another embodiment, the desired crude composition, i.e., mixtures of compounds of Formula II and compounds of Formula III, wherein R1 is methoxy (OCH3) and R2 is methyl (CH3), is obtained through contacting a compound of Formula II with Li2CO3 and methyl iodide (CH3I) in DMF (1.0 M) in a molar ratio of about 1:0.6:3 at 45° C. Upon completion, dilution of the crude composition with a polar, aprotic solvent, such as CH3CN, wherein the ratio of CH3CN:DMF is from about 2:1 to about 1:2, followed by an aqueous solution of sodium thiosulfate (Na2S2O3) with a pH from about 8 to about 1.0.5, wherein the ratio of 2.5 wt. % aqueous Na2S2O3:DMF is from about 1:2 to about 3:1, affords a precipitate which is isolable by filtration. In one embodiment, the ratio of CH3CN:DMF is about 1:2 and the ratio of 2.5% aqueous Na2S2O3:DMF is about 1:1, and the resultant solid is further purified by crystallization/precipitation from a warmed solution, about 30° C.-40° C., of the solid in a solution of a polar, aprotic solvent, such as CH3CN, by the addition of water (H2O), wherein the ratio of H2O:CH3CN is from about 1:2 to about 3:1, to give the purified compound of Formula III, and in another embodiment the ratio of H2O:CH3CN to affect precipitation of pure III is about 2:1.


In another embodiment, compounds of Formula II may be prepared by contacting compounds of Formula I (shown below) with bis-N,O-trimethylsilylacetamide (BSA) at an elevated temperature, such as 70° C., for a period of about 1 hour (h), followed by cooling and contacting the solution containing the protected pyrimidinol with a substituted benzene sulfonyl chloride, generalized by R1-PhSO2Cl, wherein R1 is as previously defined, at about 20° C.-25° C. In some embodiments, the molar ratio of the compound of Formula I to BSA and the sulfonyl chloride is about 1:3:1.1, respectively, and in another embodiment reducing the molar ratio of the reactants to about 1:1.1:1.1 affords improved yields.




embedded image


The term “alkyl” refers to a branched, unbranched, or saturated cyclic carbon chain, including, but not limited to, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tertiary butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.


The term “alkenyl” refers to a branched, unbranched or cyclic carbon chain containing one or more double bonds including, but not limited to, ethenyl, propenyl, butenyl, isopropenyl, isobutenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like.


The term “aryl” refers to any aromatic, mono- or bi-cyclic, containing heteroatoms.


The term “heterocycle” refers to any aromatic or non-aromatic ring, mono- or bi-cyclic, containing one or more heteroatoms.


The term “alkoxy” refers to an —OR substituent.


The term “halogen” or “halo” refers to one or more halogen atoms, defined as F, Cl, Br, and I.


The term “haloalkyl” refers to an alkyl, which is substituted with Cl, F, I, or Br or any combination thereof.


Throughout the disclosure, references to the compounds of Formulas I, II, III, and IV are read as also including optical isomers and salts. Exemplary salts may include: hydrochloride, hydrobromide, hydroiodide, and the like. Additionally, the compounds of Formulas I, II, III, and IV may include tautomeric forms.


Certain compounds disclosed in this document can exist as one or more isomers. It will be appreciated by those skilled in the art that one isomer may be more active than the others. The structures disclosed in the present disclosure are drawn in only one geometric form for clarity, but are intended to represent all geometric and tautomeric forms of the molecule.


In one exemplary embodiment, a method of making a compound of Formula III is provided. The method includes contacting a compound of Formula II with an alkali carbonate and an alkylating agent; and forming a compound of Formula III,




embedded image



wherein R1 is selected from the group consisting of:




embedded image



and


R2 is selected from the group consisting of:




embedded image


In a more particular embodiment, the contacting step is carried out between 22° C. and 60° C.


In another more particular embodiment of any of the above embodiments, the contacting step further includes a solvent selected from the group consisting of DMF, DMSO, DMA, NMP, and CH3CN.


In another more particular embodiment of any of the above embodiments, the alkali carbonate is selected from the group consisting of Na2CO3, K2CO3, Cs2CO3, and Li2CO3.


In another more particular embodiment of any of the above embodiments, the alkylating agent is selected from the group consisting of: alkyl halides and benzyl halides. In an even more particular embodiment, the alkyl halide and benzyl halide are selected from methyl iodide (CH3I), ethyl iodide (C2H5I), and benzyl bromide (BnBr).


In another more particular embodiment of any of the above embodiments, the alkali carbonate base is Cs2CO3, and the solvent is DMF.


In another more particular embodiment of any of the above embodiments, a molar ratio of Compound II to alkali carbonate base is from about 3:1 to about 1:1 and a molar ratio of Compound II to alkylating agent is from about 1:1 to about 3:1. In an even more particular embodiment, a molar ratio of Compound II to alkali carbonate base is about 2:1 a molar ratio of Compound H alkylating agent is 1:3.


In another more particular embodiment of any of the above embodiments, the method further includes the step of diluting a completed reaction mixture with CH3CN and 2.5% aqueous Na2S2O3. In an even more particular embodiment, a ratio of DMF to CH3CN is from about 1:1 to about 3:1 and a ratio of DMF to 2.5% aqueous Na2S2O3 is from about 1:2 to about 2:1. In a still more particular embodiment, a ratio of DMF to CH3CN is about 2:1 and a ratio of DMF to 2.5% aqueous Na2S2O3 is about 1:1.


In another embodiment, a method of preparing a compound of Formula II is provided. The method includes contacting a compound of Formula I with bis-N,O-trimethylsilylacetamide (BSA):




embedded image



and forming a compound of Formula II:




embedded image



wherein a molar ratio of compound I to bis-N,O-trimethylsilylacetamide (BSA) is 1:1.1 and the contacting step is carried out at about 22° C. to about 70° C.


In a more particular embodiment, the contacting step further includes contacting compound I with CH3CN.


In another more particular embodiment of any of the above embodiments, the method comprises contacting a BSA treated reaction mixture with an arylsulfonyl chloride.


In another more particular embodiment of any of the above embodiments, a molar ratio of Compound I to arylsulfonyl chloride is from about 1:2 to about 2:1. In an even more particular embodiment, a molar ratio of Compound I to arylsulfonyl chloride is 1:1.1.


The embodiments described above are intended merely to be exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the invention and are encompassed by the appended claims.







DETAILED DESCRIPTION

5-Fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one as shown in Examples 1-2.


Example 1: Preparation of 4-amino-5-fluoro-1-(phenylsulfonyl)pyrimidin-2(1H)-one (1)



embedded image


To a dry 500 milliliter (mL) round bottom flask equipped with a mechanical stirrer, nitrogen inlet, addition funnel, thermometer, and reflux condenser were added 5-fluorocytocine (20.0 grams (g), 155 millimole (mmol)) and CH3CN (100 mL). To the resulting mixture was added BSA (34.7 g, 170 mmol)) in one portion and the reaction was warmed to 70° C. and stirred for 30 minutes (min). The resulting homogeneous solution was cooled to 5° C. with an ice bath and treated dropwise with benzenesulfonyl chloride. The reaction was stirred at 0° C.-5° C. for 1 h and then overnight at room temperature. The resulting pale yellow suspension was poured into cold H2O (1.5 liters (L)) and stirred vigorously for 1 h. The resulting solid was collected by vacuum filtration, washed with H2O, and dried under vacuum overnight at 40° C. to give 4-amino-5-fluoro-1-(phenylsulfonyl)pyrimidin-2(1H)-one (29.9 g, 72%) as a powdery white solid: 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.35-8.26 (m, 2H), 8.07-7.98 (m, 2H), 7.84-7.74 (m, 1H), 7.72-7.61 (m, 2H); 19F NMR (376 MHz, DMSO-d6) δ −163.46; ESIMS m/z 270 ([M+H]+).


The following compounds 1-3 in Table 1a were made in accordance with the reaction depicted in Scheme 1 and the procedures described in Example 1. Characterization data for compounds 1-3 are shown in Table 1b.




embedded image












TABLE 1a





Compound


Yield


Number
R1
Appearance
(%)







1
H
Powdery White Solid
72


2
CH3
Powdery White Solid
61


3
OCH3
Powdery White Solid
57



















TABLE 1b









13C NMR or



Compound
Mass


19F NMR



Number
Spec.

1H NMR (δ)a

(δ)b,c







1
ESIMS

1H NMR (DMSO-


19F NMR




m/z 270
d6) δ 8.56 (s, 1H),
(DMSO-d6) δ −163.46



([M + H]+)
8.35-8.26 (m,




2H),




8.07-7.98 (m, 2H),




7.84-7.74 (m, 1H),




7.72-7.61 (m, 2H)


2
ESIMS

1H NMR (DMSO-


19F NMR




m/z 284
d6) δ 8.54 (s, 1H),
(DMSO-d6) δ −163.62



([M + H]+)
8.40-8.16 (m,




2H),




8.05-7.76 (m, 2H),




7.66-7.36 (m, 2H),




2.41 (s, 3H)


3
ESIMS

1H NMR (CDCl3)


19F NMR




m/z 300
δ 8.10-7.91 (m,
(CDCl3) δ −158.58



([M + H]+)
2H), 7.73 (d,




J = 5.4 Hz, 2H),




7.11-6.94 (m, 2H),




3.90 (s, 3H), 3.32




(d, J = 0.6 Hz,




3H)






aAll 1H NMR data measured at 400 MHz unless otherwise noted.




bAll 13C NMR data measured at 101 MHz unless otherwise noted.




cAll 19F NMR data measured at 376 MHz unless otherwise noted.







Example 2: Preparation of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2(1H)-one (5)



embedded image


To a mixture of 4-amino-5-fluoro-1-tosylpyrimidin-2(1H)-one (5.66 g, 20 mmol) and Li2CO3 (0.880 g, 12.0 mmol) in DMF (20 mL) was added CH3I (8.52 g, 60.0 mmol), and the resulting mixture was warmed to 40° C. and stirred for 5 h. The reaction mixture was cooled to room temperature, diluted with CH3CN (10 mL), and treated with 2.5% aqueous Na2S2O3 (20 mL). The resulting mixture was stirred at room temperature for 10 min and the solids were collected by filtration. The filter cake was washed with aqueous CH3CN (10% CH3CN in H2O) and air dried for 2 h. The cake was dissolved in CH3CN (15 mL) at 40° C. and the solution was treated with H2O (30 mL). The resulting suspension was cooled to room temperature, stirred for 2.5 h, and filtered. The filter cake was again washed with 10% aqueous CH3CN and then dried under vacuum at 50° C. to give the title compound (2.70 g, 45%) as a white solid: mp 156-158° C.; 3H NMR (400 MHz, DMSO-d6) δ 8.54 (d, J=2.3 Hz, 1H), 7.99 (dd, J=6.0, 0.6 Hz, 1H), 7.95-7.89 (m, 2H), 7.53-7.45 (m, 2H), 3.12 (d, J=0.7 Hz, 3H), 2.42 (s, 3H); 19F NMR (376 MHz, DMSO-d6) −157.86 (s); ESIMS m/z 298 ([M+H]+).


The following compounds 4-6 in Table 2a were made in accordance with the reaction depicted in Scheme 2 and the procedures described in Example 2. Characterization data for compounds 4-6 are shown in Table 2b.




embedded image













TABLE 2a





Compound



Yield


Number
R1
R2
Appearance
(%)







4
H
CH3
White Solid
64


5
CH3
CH3
White Solid
45


6
OCH3
CH3
White Solid
62



















TABLE 2b









13C NMR or



Compound
Mass


19F NMR



Number
Spec.

1H NMR (δ)a

(δ)b,c







4
ESIMS

1H NMR (CDCl3) δ


19F NMR




m/z 284
8.14-8.02 (m, 2H),
(CDCl3) δ −158.05



([M + H]+)
7.88-7.67 (m, 3H),




7.67-7.50 (m, 2H),




3.31 (d, J = 0.7 Hz,




3H)


5
ESIMS

1H NMR (DMSO-d6)


19F NMR




m/z 298
δ 8.54 (d, J = 2.3 Hz,
(DMSO-d6)



([M + H]+)
1H), 7.99 (dd, J = 6.0,
δ 157.86 (s)




0.6 Hz, 1H),




7.95-7.89 (m, 2H),




7.53-7.45 (m, 2H),




3.12 (d, J = 0.7 Hz,




3H), 2.42 (s, 3H)


6
ESIMS

1H NMR (CDCl3) δ


19F NMR




m/z 314
8.10-7.91 (m, 2H),
(CDCl3) δ −158.58



([M + H]+)
7.73 (d, J = 5.4 Hz,




2H), 7.11-6.94 (m,




2H), 3.90 (s, 3H),




3.32 (d, J = 0.6 Hz,




3H)






aAll 1H NMR data measured at 400 MHz unless otherwise noted.




bAll 13C NMR data measured at 101 MHz unless otherwise noted.




cAll 19F NMR data measured at 376 MHz unless otherwise noted.






Claims
  • 1. A method of making compounds of Formula III, including the steps of: contacting a compound of Formula II with an alkali carbonate and an alkylating agent,
  • 2. The method of claim 1, wherein a) the contacting step is carried out between 22° C. and 60° C.;b) the contacting step further includes a solvent selected from the group consisting of: DMF, DMSO, DMA, NMP, and CH3CN;c) the alkali carbonate is selected from the group consisting of: Na2CO3, K2CO3, Cs2CO3, and Li2CO3;d) the alkylating agent is selected from the group consisting of: alkyl halides and benzyl halides; and/ore) the method further includes the step of diluting a completed reaction mixture with CH3CN and 2.5% aqueous Na2S2O3.
  • 3. The method of claim 2, wherein the alkyl halides and benzyl halides are selected from the group consisting of: methyl iodide, ethyl iodide, and benzyl bromide.
  • 4. The method of claim 2, wherein the alkali carbonate is Cs2CO3, and the solvent is DMF.
  • 5. The method of claim 1, wherein the molar ratio of the compound of Formula II to the alkylating agent is from 1:1 to 3:1.
  • 6. The method of claim 1, wherein the molar ratio of the compound of Formula II to the alkali carbonate is 2:1 and the molar ratio of the compound of Formula II to the alkylating agent is 1:3.
  • 7. The method of claim 3, wherein the method further includes the step of diluting a completed reaction mixture with CH3CN and 2.5% aqueous Na2S2O3 and the ratio of DMF to CH3CN is from 1:1 to 3:1 and the ratio of DMF to 2.5% aqueous Na2S2O3 is from 1:2 to 2:1.
  • 8. A method of preparing a compound of Formula II, including the steps or: contacting a compound of Formula I:
  • 9. The method of claim 8, wherein a) the contacting step further includes contacting compound I with CH3CN; and/orb) the method further comprises a step of contacting a bis-N,O-trimethylsilylacetamide treated reaction mixture with an arylsulfonyl chloride.
  • 10. The method of claim 9, wherein the molar ratio of the compound of Formula I to the arylsulfonyl chloride is from 1:2 to 2:1.
  • 11. The method of claim 2, wherein a) the contacting step is carried out between 22° C. and 45° C.;b) the solvent selected from the group consisting of: DMF, DMA, and NMP;c) the alkali carbonate is Li2CO3; and/ord) the alkylating agent is an alkyl halide and the alkyl halide is methyl iodide.
  • 12. The method of claim 7, wherein the ratio of DMF to CH3CN is 2:1 and the ratio of DMF to 2.5% aqueous Na2S2O3 is 1:1.
  • 13. The method of claim 10, wherein the molar ratio of the compound of Formula I to the arylsulfonyl chloride is 1:1.1.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Ser. No. 14/584,347, filed Dec. 29, 2014, which claims the benefit of U.S. Provisional Patent Application Ser. Nos. 61/922,582 and 61/922,572, each filed Dec. 31, 2013, the disclosures of each are expressly incorporated by reference herein.

US Referenced Citations (54)
Number Name Date Kind
3309359 Duschinsky et al. Mar 1967 A
3368938 Berger et al. Feb 1968 A
3635977 Lutz et al. Jan 1972 A
3868373 Hoffer Feb 1975 A
4009272 Konig et al. Feb 1977 A
4845081 Sloan Jul 1989 A
4996208 Lindner et al. Feb 1991 A
5962489 Mueller et al. Oct 1999 A
6066638 Bereznak et al. May 2000 A
6617330 Walter Sep 2003 B2
7914799 Patashnik et al. Mar 2011 B2
8263603 Boebel et al. Sep 2012 B2
8318758 Boebel et al. Nov 2012 B2
8470839 Boebel et al. Jun 2013 B2
8552020 Pobanz et al. Oct 2013 B2
8658660 Boebel et al. Feb 2014 B2
8916579 Boebel et al. Dec 2014 B2
9000002 Pobanz et al. Apr 2015 B2
9006259 Webster et al. Apr 2015 B2
9271497 Lorsbach et al. Mar 2016 B2
9321734 Lorsbach et al. Apr 2016 B2
9526245 Owen et al. Dec 2016 B2
9532570 Owen et al. Jan 2017 B2
9538753 Owen et al. Jan 2017 B2
20030039667 Jira et al. Feb 2003 A1
20080004253 Branstetter et al. Jan 2008 A1
20080269238 Sugihara et al. Oct 2008 A1
20090203647 Benko et al. Aug 2009 A1
20090269238 Anada et al. Oct 2009 A1
20100022538 Boebel et al. Jan 2010 A1
20100029482 Benko et al. Feb 2010 A1
20100029483 Iskandar et al. Feb 2010 A1
20110034490 Boebel et al. Feb 2011 A1
20110034491 Boebel et al. Feb 2011 A1
20110034492 Boebel et al. Feb 2011 A1
20110034493 Boebel et al. Feb 2011 A1
20110053891 Boebel et al. Mar 2011 A1
20110263627 Boebel Oct 2011 A1
20130045984 Boebel Feb 2013 A1
20140011824 Pobanz et al. Jan 2014 A1
20150111851 Boebel et al. Apr 2015 A1
20150181874 Lorsbach et al. Jul 2015 A1
20150181875 Owen et al. Jul 2015 A1
20150181883 Lorsbach et al. Jul 2015 A1
20150183749 Choy Jul 2015 A1
20150183750 Choy Jul 2015 A1
20150191436 Boebel et al. Jul 2015 A1
20150342188 Lorsbach et al. Dec 2015 A1
20150353506 Lorsbach et al. Dec 2015 A1
20150359225 Lorsbach et al. Dec 2015 A1
20160192653 Lorsbach et al. Jul 2016 A1
20160198711 Lorsbach et al. Jul 2016 A1
20160280663 Choy et al. Sep 2016 A1
20170008855 Boebel et al. Jan 2017 A1
Foreign Referenced Citations (34)
Number Date Country
0102908 Mar 1984 EP
0139613 May 1985 EP
0332579 Sep 1989 EP
0230922 Apr 2002 EP
08770722 Apr 2003 EP
1952689 Aug 2008 EP
1461184 Jan 1977 GB
6001793 Jan 1994 JP
2002-530409 Sep 2002 JP
2013-501728 Aug 2010 JP
2012-502905 Feb 2012 JP
597644 Sep 2014 NZ
WO 9733890 Sep 1997 WO
WO 2008083465 Jul 2008 WO
WO 2009094442 Jul 2009 WO
WO 2010047866 Apr 2010 WO
WO 2010085377 Jul 2010 WO
WO 2011017538 Feb 2011 WO
WO 2011017540 Feb 2011 WO
WO 2011017544 Feb 2011 WO
WO 2011017545 Feb 2011 WO
WO 2011017547 Feb 2011 WO
WO 2011043876 Apr 2011 WO
WO 2011137002 Nov 2011 WO
WO 2013025795 Feb 2013 WO
WO 2015103262 Jul 2013 WO
WO 2014105821 Jul 2014 WO
WO 2014105841 Jul 2014 WO
WO 2014105844 Jul 2014 WO
WO 2014105845 Jul 2014 WO
WO 2015103142 Jul 2015 WO
WO 2015103144 Jul 2015 WO
WO 2015103259 Jul 2015 WO
WO 2015103261 Jul 2015 WO
Non-Patent Literature Citations (108)
Entry
PCT International Search Report dated Apr. 8, 2015 in connection with PCT/US2014/072566 (WO 2015/103142), filed Dec. 29, 2014.
International Preliminary Report on Patentability dated Jul. 5, 2016 in connection with PCT/US2014/072566 (WO 2015/103142), filed Dec. 29, 2014.
Written Opinion of the International Searching Authority dated Apr. 8, 2015 in connection with PCT/US2014/072566 (WO 2015/103142), filed Dec. 29, 2014.
PCT International Search Report dated Apr. 2, 2015 in connection with PCT/US2014/072569 (WO 2015/103144), filed Dec. 29, 2014.
Written Opinion of the International Searching Authority dated Apr. 2, 2015 in connection with PCT/US2014/072569 (WO 2015/103144), filed Dec. 29, 2014.
Bera et al. (2002) “Nucleosides with furanyl scaffolds.” Tetrahedron, Elsevier Science Publishers. 58(24): 4865-4871.
Chiacchio et al. (2003) “Enantioselective Syntheses and Cytotoxicity of N,O-Nucleosides.” J. of Medicinal Chemistry, American Chemical Society. 46(1): 3696-3702.
Duschinsky et al. (1966) “Nucleosides. XXXIII. N4-Acylated 5-Fluorocytosines and a Direct Synthesis of 5-Fluoro-2′-deoxycytidine” J. of Medicinal Chemistry. 9(4): 566-572.
Dushinsky et al. (1964) “Cytosine derivatives.” CAPLUS Abstract 61:18527.
Gabriella et al. (1963) “Some 5-fluorosulfailamidopyrimidines.” Gazzette Chimica Italiana. 93(10): 1268-1278.
Kulikowski et al. (1978) “Methylation and tautomerism of 5-fluorocytosine nucleosides and their analogues.” J. Nucleic Acids Research, Special Publication. 4(1): S7-S10.
Lewis et al. (1995) “Synthesis and in vitro anti-human cytomegalovirus (hcmv) activity of certain alkenyl substituted cytosines and 5-halocytosines.” J. of Heterocyclic Chemistry. 32(5): 1513-1515.
Liang et al. (2007) “A facile synthesis and herbicidal activities of novel fluorine-containing thiazolo[4,5-d] pyrimidin-7(6H)-ones.” J. of Fluorine Chemistry , 128(7): 879-884.
Robins et al. (1972) “A direct synthesis of 5-fluorocytosine and its nucleosides using trifluromethyl hypofluorite.” J. of the Chemical Society, Chemical Communications. 1(1): 18.
Waring (2009) “Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability.” Bioorganic & Medicinal Chemistry Letters, 19(10): 2844-2851.
Zhang et al. (1989) “Improved method for synthesis of 5-fluorocytosine (5-FC).” CAPLUS Abstract, 111:134074.
International Preliminary Report on Patentability dated Jul. 5, 2016 in connection with PCT/US2014/072569 (WO 2015/103144), filed Dec. 29, 2014.
International Search Report dated Sep. 21, 2010 in connection with PCT/US2010/044579 (WO 2011/017540), filed Aug. 5, 2010.
International Search Report dated Sep. 21, 2010 in connection with PCT/US2010/044592 (WO 2011/017547), filed Aug. 5, 2010.
International Search Report dated Sep. 23, 2010 in connection with PCT/US2010/044576 (WO 2011/017538), filed Aug. 5, 2010.
PCT International Search Report dated Jul. 5, 2011 in connection with PCT/US2011/033203 (WO 2011/137002), filed Apr. 20, 2011.
Written Opinion of the International Searching Authority dated Jul. 5, 2011 in connection with PCT/US2011/033203 (WO 2011/137002), filed Apr. 20, 2011.
International Preliminary Report on Patentability dated Oct. 30, 2012 in connection with PCT/US2011/033203 (WO 2011/137002), filed Apr. 20, 2011.
International Search Report dated Oct. 15, 2012 in connection with PCT/US2012/050930 (WO 2013/025795), filed Aug. 15, 2012.
Written Opinion of the International Searching Authority fsyrf Oct. 15, 2012 in connection with PCT/US2012/050930 (WO 2013/025795), filed Aug. 15, 2012.
International Preliminary Report on Patentability dated Feb. 18, 2014 in connection with PCT/US2012/050930 (WO 2013/025795), filed Aug. 15, 2012.
PCT International Search Report dated Apr. 28, 2015 in connection with PCT/US2014/072745 (WO 2015/103259), filed Dec. 30, 2014.
International Preliminary Report on Patentability dated Jul. 5, 2016 in connection with PCT/US2014/072745 (WO 2015/103259), filed Dec. 30, 2014.
Written Opinion of the International Searching Authority dated Apr. 28, 2015 in connection with PCT/US2014/072745 (WO 2015/103259), filed Dec. 30, 2014.
International Search Report dated Apr. 29, 2015 in connection with PCT/US2014/072747 (WO 2015/103261), filed Dec. 30, 2014.
International Preliminary Report on Patentability dated Jul. 5, 2016 in connection with PCT/US2014/072747 (WO 2015/103261), filed Dec. 30, 2014.
Written Opinion of the International Searching Authority dated Apr. 29, 2015 in connection with PCT/US2014/072747 (WO 2015/103261), filed Dec. 30, 2014.
PCT International Search Report dated May 21, 2015 in connection with PCT/US2014/072748 (WO 2015/103262), filed Dec. 30, 2014.
International Preliminary Report on Patentability dated Jul. 5, 2016 in connection with PCT/US2014/072748 (WO 2015/103262), filed Dec. 30, 2014.
Written Opinion of the International Searching Authority dated May 21, 2015 in connection with PCT/US2014/072748 (WO 2015/103262), filed Dec. 30, 2014.
International Search Report dated Jan. 22, 2009 in connection with PCT International Application No. PCT/US/2009/031683 (WO 2009/094442), filed Jan. 22, 2009.
International Search Report dated Mar. 14, 2011 in connection with PCT/US/2011/020351 (WO 2011/085084), filed Jan. 6, 2011.
International Search Report dated Oct. 1, 2010 in connection with PCT/US/2010/044588 (WO 2011/017545), filed Aug. 5, 2010.
International Search Report dated Oct. 9, 2010 in connection with PCT International Application No. PCT/US/2012/050931 (WO 2013/025796), filed Aug. 15, 2012.
International Search Report dated Apr. 22, 2011 in connection with PCT/US/2010/060792 (WO 2011/084611), filed Dec. 16, 2010.
Nov. 10, 2011 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 13/090,616.
Feb. 9, 2012 Response to Nov. 10, 2011 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 13/090,616.
May 14, 2013 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 13/586,450.
Aug. 14, 2013 Response to May 14, 2013 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 13/586,450.
Mar. 4, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,347.
Jun. 4, 2015 Response to Mar. 4, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,347.
Jul. 2, 2015 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,347.
Sep. 2, 2015 Response to Jul. 2, 2015 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,347.
Sep. 9, 2015 Advisory Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,347.
Nov. 23, 2016 Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 15/173,493.
Mar. 5, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,368.
Jun. 4, 2015 Response to Mar. 5, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,368.
Jul. 2, 2015 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,368.
Sep. 2, 2015 Response to Jul. 2, 2015 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,368.
Sep. 10, 2015 Advisory Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/584,368.
Dec. 1, 2016 Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 15/173,529.
Dec. 18, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,945.
Mar. 16, 2016 Response to Dec. 18, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,945.
Apr. 11, 2016 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,945.
Aug. 11, 2016 Response to Apr. 11, 2016 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,945.
Dec. 18, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,952.
Mar. 16, 2016 Response to Dec. 18, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,952.
Apr. 12, 2016 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,952.
Aug. 11, 2016 Response to Apr. 12, 2016 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,952.
Dec. 18, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,962.
Mar. 16, 2016 Response to Dec. 18, 2015 Non-Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,962.
Apr. 12, 2016 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,962.
Aug. 12, 2016 Response to Apr. 12, 2016 Final Office Action issued by the U.S. Patent and Trademark Office in connection with U.S. Appl. No. 14/585,962.
Oct. 5, 2016 Communication pursuant to Rules 161(2) and 162 EPC issued by the European Patent Office in connection with European Patent Application No. 14877285.8.
Dec. 23, 2016 First Examination Report issued by the Australian Patent Office in connection with Australian Patent Application No. 2014373959.
Aug. 9, 2016 Office Action issued by the Colombian Patent Office in connection with Colombian Patent Application No. NC2016-0000512.
Jul. 14, 2016 Office Action issued by the Cuban Patent Office in connection with Cuban Patent Application No. 2016-0099 (including English language translation).
Oct. 6, 2016 Response to Jul. 14, 2016 Office Action issued by the Cuban Patent Office in connection with Cuban Patent Application No. 2016-0099.
Oct. 5, 2016 Communication pursuant to Rules 161(2) and 162 EPC issued by the European Patent Office in connection with European Patent Application No. 14875976.4.
Dec. 23, 2016 First Examination Report issued by the Australian Patent Office in connection with Australian Patent Application No. 2014373961.
Jan. 12, 2017 First Examination Report issued by the New Zealand Patent Office in connection with New Zealand Patent Application No. 722439.
Jan. 12, 2017 First Examination Report issued by the New Zealand Patent Office in connection with New Zealand Patent Application No. 722438.
Jun. 24, 2013 Supplemental European Search Report issued by the EPO in connection with European Patent Application No. 11775446.5, filed Apr. 20, 2011.
Sep. 25, 2014 Communication pursuant to Article 94(3) EPC issued by the European Patent Office in connection with European Patent Application No. 11775446.5-1462.
Feb. 4, 2015 Response to Sep. 25, 2014 Communication pursuant to Article 94(3) EPC issued by the European Patent Office in connection with European Patent Application No. 11775446.5-1462.
European Search Opinion issued by the EPO in connection with European Patent Application No. 11775446.5.
Feb. 3, 2014 Response to European Search Opinion issued by the EPO in connection with European Patent Application No. 11775446.5.
Mar. 23, 2015 Response to Aug. 28, 2014 First Examination Report issued by the Australian Patent Office in connection with Australian Patent Application No. 2011245544.
Jan. 11, 2017 Office Action issued by the Canadian Patent Office in connection with Canadian Patent Application No. 2,797,226.
Aug. 25, 2015 Office Action issued by the Chilean Patent Office in connection with Chilean Patent Application No. 2979-2012.
May 26, 2016 Office Action issued by the Chilean Patent Office in connection with Chilean Patent Application No. 2979-2012.
Aug. 22, 2016 Response to May 26, 2016 Office Action issued by the Chilean Patent Office in connection with Chilean Patent Application No. 2979-2012.
Oct. 17, 2013 Office Action issued by the Chinese Patent Office in connection with Chinese Patent Application No. 201180031680.8.
Feb. 28, 2014 Response to Oct. 17, 2013 Office Action issued by the Chinese Patent Office in connection with Chinese Patent Application No. 201180031680.8.
May 23, 2014 Office Action issued by the Chinese Patent Office in connection with Chinese Patent Application No. 201180031680.8.
Sep. 24, 2013 Office Action issued by the Colombian Patent Office in connection with Colombian Patent Application No. 12213540.
Dec. 18, 2013 Response to Sep. 24, 2013 Office Action issued by the Colombian Patent Office in connection with Colombian Patent Application No. 12213540.
Jun. 22, 2015 Response to Mar. 22, 2015 Office Action issued by the Israeli Patent Office in connection with Israeli Patent Application No. 222646.
Feb. 10, 2015 Office Action issued by the Japanese Patent Office in connection with Japanese Patent Application No. 2013-508042.
May 10, 2015 Response to Feb. 10, 2015 Office Action issued by the Japanese Patent Office in connection with Japanese Patent Application No. 2013-508042.
Jul. 3, 2014 Response to May 26, 2014 Office Action issued by the Mexican Patent Office Mexican Patent Application No. MX/a/2012/012530.
Jun. 14, 2013 First Examination Report issued by the New Zealand Patent Office in connection with New Zealand Patent Application No. 603151.
Oct. 1, 2013 Response to Jun. 14, 2013 First Examination Report issued by the New Zealand Patent Office in connection with New Zealand Patent Application No. 603151.
Jun. 17, 2016 Office Action issued by the Filipino Patent Office in connection with Filipino Patent Application No. 1/2012/502138.
Sep. 28, 2016 Office Action issued by the Filipino Patent Office in connection with Filipino Patent Application No. 1/2012/502138.
Jan. 19, 2015 Office Action issued by the Russian Patent Office in connection with Russian Patent Application No. 2012150293.
Apr. 19, 2015 Response to Jan. 19, 2015 Office Action issued by the Russian Patent Office in connection with Russian Patent Application No. 2012150293.
Apr. 16, 2014 Office Action issued by the Ukrainian Patent Office in connection with Ukrainian Patent Application No. 2012 13412.
Oct. 30, 2014 Response to Apr. 16, 2014 Office Action issued by the Ukrainian Patent Office in connection with Ukrainian Patent Application No. 2012 13412.
Nov. 20, 2016 Response to Jul. 20, 2016 Notice Before Examination issued by the Israeli Patent Office in connection with Israeli Patent Application No. 246511.
Nov. 20, 2016 Response to Jul. 20, 2016 Notice Before Examination issued by the Israeli Patent Office in connection with Israeli Patent Application No. 246512.
Woese et al, (1990) “Towards a natural system of organisms: Proposal for the domains Archaea, Bacteria, and Eucarya.” Proc. Acad. Sci., 87:4576-4579.
Jaworski et al. (1990) “Infrared spectra and tautomerism of 5- fluorocytosine, 5-bromocytosine and 5-iodocytosine Matrix isolation and theoretical ab initio studies.” J. of Molecular Structure. 223: 63-92 (Abstract).
Related Publications (1)
Number Date Country
20160280662 A1 Sep 2016 US
Provisional Applications (2)
Number Date Country
61922572 Dec 2013 US
61922582 Dec 2013 US
Continuations (1)
Number Date Country
Parent 14584347 Dec 2014 US
Child 15173493 US